1:1 Bonus Issue Alert! Remus Pharma Declares Bonus Shares; Record Date Set for July 4, 2025: Check Eligibility

Remus Pharmaceuticals Limited, a fast-growing player in the Indian pharmaceutical sector, has announced a 1:1 bonus share issue to reward its shareholders and enhance market participation. According to the company's recent regulatory filing with the National Stock Exchange (NSE), Friday, July 4, 2025, has been fixed as the 'Record Date' for determining the eligibility of shareholders entitled to receive the bonus equity shares.

Remus Pharma Bonus Issue Recording Date

"Pursuant to the provisions of Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has fixed Friday, July 04, 2025 as 'Record Date' for the purpose of determining the eligibility of Shareholders entitled for issuance of Bonus Equity Shares in the ratio of 1:1," said the company in a regulatory filing.

1:1 Bonus Share on July 4, 2025

"1 (One) new fully paid-up Equity Shares of ₹ 10/- (Rupees Ten only) each for every 1 (One) existing fully paid-up Equity Share of ₹ 10/- (Rupees Ten only) each held by them on the aforesaid Record Date in accordance with the approval of the shareholders obtained through Postal Ballot on June 23, 2025."

This means that all shareholders whose names appear in the Register of Members or in the List of Beneficial Owners maintained by the depositories as on 4th July 2025 will be entitled to receive 1 (one) fully paid-up equity share of Rs 10 each for every 1 (one) fully paid-up equity share of Rs 10 they currently hold.

The bonus issue is being made in accordance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and follows shareholder approval secured through a postal ballot on 23rd June 2025.

Financial Performance of Remus Pharma

Remus Pharmaceuticals Limited has reported robust financial performance for the second half of the financial year 2024-25 (H2 FY25), highlighting its continued expansion in the pharmaceutical sector. The company recorded a substantial year-on-year (YoY) increase of nearly 88% in revenue from operations, which surged from Rs 185 crore in H2 FY24 to Rs 348 crore in H2 FY25.

While the revenue performance was notably strong, net profit showed a moderate increase, rising from Rs 19 crore in H2 FY24 to Rs 21 crore in H2 FY25, which translates to a YoY growth of 10.5%. The comparatively slower pace of profit growth, despite the sharp rise in revenue, could be attributed to increased input costs, higher marketing and distribution expenses, or ongoing investments in R&D and infrastructure aimed at scaling future operations.